在DLBCL中,BCL6赋予了对HDAC抑制剂的耐药性
Gao Fan1, Yuchen Zhang2, Qi Li2
1Department of Cell Biology, School of Biology & Basic Medical Sciences, Suzhou Medical College of Soochow University, Suzhou, China.
Biochemical pharmacology
|August 5, 2024
概括
奇胺通过影响关键通路,有效抑制扩散性大B细胞淋巴瘤 (DLBCL). 列纳利多米德通过向BCL6恢复了耐药DLBCL的敏感性,提供了个性化的治疗方法.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 扩散性大B细胞淋巴瘤 (DLBCL) 是一种具有攻击性的非霍奇金淋巴瘤,对常规化疗反应不佳.
- 在DLBCL中观察到减少的基因素乙化,这表明基因素脱乙酶抑制剂 (HDACis) 有作用.
- 奇胺是一种HDACi,显示出潜力,但需要在DLBCL中进行进一步的研究.
研究的目的:
- 评估在DLBCL中奇达胺的疗效.
- 阐明基达胺的作用和抵抗背后的分子机制.
- 确定潜在的治疗策略来克服奇达胺耐药性.
主要方法:
- 在体外和体外DLBCL模型.
- 高通量RNA测序用于分析信号通路的变化.
- 调查BCL6在基达胺耐药性中的作用和莱纳利多米德对BCL6.6的影响.
主要成果:
- 奇达米德在体外和体内显著抑制了DLBCL生长.
- 奇胺调节了关键通路,包括MAPK,MYC和p53.
- 增加的BCL6表达通过抑制组织素乙化,使其对基达米德产生耐药性;利那利多米德通过促进BCL6降解来逆转这种耐药性.
结论:
- 奇达胺是DLBCL的一个有前途的治疗剂,影响多个信号通路.
- 鉴定出BCL6是基达胺耐药性的关键调解者.
- 与莱纳利多米德联合治疗以抑制BCL6为DLBCL提供了潜在的个性化治疗策略.
更多相关视频
相关概念视频
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
02:30Histone Variants at the Centromere
4.3K
Histone variants are the histone proteins with structural and sequence variations. These variants may be regarded as “mutant” forms that replace their canonical histone counterparts in the nucleosomes. Specific post-translational modifications on the histone variants enable further chromatin complexity and regulate tissue-specific gene expression. The most common histone variants are from histone H2A, H2B, and linker histone H1 families. However, several variants of histone H3...
4.3K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
01:31The Intrinsic Apoptotic Pathway
6.4K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K